WAVEMAN · COMPANY

SXTC · China Sxt Pharmaceuticals, Inc.

LIVE

TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475

← ALL COMPANIES

SXTC

Name: China SXT Pharmaceuticals, Inc. (SXTC) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

China SXT Pharmaceuticals, Inc.

PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0001723980

SEC FILINGS☆ WATCH

INSIDER NET · 180D

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

13F, latest reported quarter

REVENUE GROWTH

-34.6%

XBRL, annual

NET MARGIN

-545.2%

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

no Form 4 purchases or sales on file

CONGRESS

no member of Congress has reported trading it

FUNDS

1 fund added or opened last quarter

REVENUE

-34.6% year over year

below 78% of Pharma & Biotech

MARGIN

-545.2% net margin

below 83% of Pharma & Biotech

BUYBACKS

no share repurchases reported

SHORT

no short interest reported

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

The complete filing record, in one place.

The record shows 1 funds added last quarter. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

UTHR CPIX MRNA REGN LLY ALNY ELF CITR MDGL DNA VRTX NUVL

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

No insider purchases or sales are on record for China SXT Pharmaceuticals, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER

FILED

VALUE

no insider purchases or sales on record

0 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see the full history, the screener and CSV export, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

Caitong International Asset Management Co., Ltd

2.0 sh

UBS Group AG

1.0 sh

ROYAL BANK OF CANADA

13.0 sh

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

FORM 144

No planned-sale notices

No insider has notified an intent to sell. This is the panel to watch after a run-up.

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2026-03	2025-03	2024-03	2023-03
REVENUE	$1.1M	$1.7M	$1.9M	$2.0M
GROSS PROFIT	$248.7K	$367.4K	$554.0K	$426.3K
OPERATING INCOME	$-7.1M	$-2.7M	$-2.5M	$-5.6M
NET INCOME	$-6.2M	$-3.3M	$-3.1M	$-5.9M
EPS (DILUTED)	-9.13	-348.17	-4,285.66	-177.84
OPERATING CASH FLOW	$-4.0M	$-2.3M	$-1.9M	$-80.8K
CASH	$28.2M	$18.1M	$12.1M	$17.4M
LONG-TERM DEBT	$644.4K	$96.3K	$117.1K	$117.9K

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE